Anavex Life Sciences Corp.
AVXL · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $101 | $116 | $121 | $132 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $1 | $1 | $3 | $2 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | -$1 | $1 | $1 | $1 |
| Total Curr. Assets | $101 | $117 | $124 | $136 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $0 | $0 | $0 | $0 |
| Other Assets | $1 | $0 | $0 | $0 |
| Total Assets | $102 | $117 | $124 | $136 |
| Liabilities | – | – | – | – |
| Payables | $7 | $7 | $5 | $10 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $1 | $1 | $1 | $1 |
| Other Curr. Liab. | $4 | $10 | $8 | $5 |
| Total Curr. Liab. | $11 | $17 | $13 | $15 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $11 | $17 | $13 | $15 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$373 | -$359 | -$348 | -$336 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $463 | $459 | $459 | $456 |
| Total Equity | $91 | $100 | $111 | $120 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $102 | $117 | $124 | $136 |
| Net Debt | -$101 | -$116 | -$121 | -$132 |